EUCTR2018-000230-35-IT进行中（未招募）1 期
Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced Ovarian cancer relapsing after Platinum-based treatment within Six months) - TROOPS MITO30
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS0 个研究点目标入组 66 人开始时间: 2021年6月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Age =18 years.
- •2.Provision of written informed consent prior to any study specific procedures.
- •3.Patients willing and able to comply with the protocol for the duration of the study, including undergoing treatment and scheduled visits and examinations.
- •4.Patients with histologically proven high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal cancer
- •5.Patients who have received at least one platinum based regimen and relapsing after a maximum of two previous lines of chemotherapy. Any immunotherapy administered will not be considered as a prior line of therapy. Use of biological agents, such as bevacizumab, in combination with previous lines of chemotherapy will be allowed.
- •6.Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary cancer must be available for histological revision in one of the participating centers prior to enrolment. After enrolment, FFPE must be shipped to Coordinating Center for ancillary studies, under subscription of the specific biomarker ICF.
- •7.One or two previous lines of chemotherapy (to be eligible patient should have received at least one line of platinum-based chemotherapy)
- •8.Measurable disease according to RECIST v1.1. Baseline evaluations must be completed within 28 days prior to enrollment with computed tomography (CT) or magnetic resonance imaging (MRI).
- •9.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0/1.
- •10.Estimated life expectancy = 16 weeks.
- •11.Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1
- •Postmenopausal is defined as:
- •-Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments or chemotherapy;
- •-LH and FSH levels in the post menopausal range for women under 55;
- •-Amenorrheic for 1 year for women = 55;
- •-Radiation-induced oophorectomy with last menses >1 year ago;
- •-Surgical sterilisation (bilateral oophorectomy or hysterectomy).
- •12.Left Ventricular Ejection Fraction = 50% and/or above lower institutional limit of normality
- •13.Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of treatment:
- •Hemoglobin > 10.0 g/dl with no blood transfusion in the past 28 days
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Platelet count ¿ 150,000/µl
- •Total bilirubin < upper limit of normal (ULN)
- •Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x ULN
- •Alkaline phosphatase < 2.5 x ULN (in case alkaline phosphatase >2.5 x ULN, consider hepatic isoenzymes 5-nucleotidase or gamma glutamyl transpeptidase (GGT) to rule out bone origin).
- •PT-INR/PTT < 1.5 x ULN (Patients who are being therapeutically anticoagulated with an agent such as warfarin, direct oral anticoagulation agents (DOACs) or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Patients treated with warfarin or DOACs must be shifted to low molecular weight heparin/fondaparinux)
- •Serum creatinine < 1.5 x ULN or creatinine clearance = 60 ml/min
- •Albumin = 25 g/l
- •Creatine phosphokinase (CPK) = 2.5 x ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 46
- •F.1.3 Elderly (>=65 years) yes
排除标准
- •2.Previous enrolment in the present study.
- •3.Participation in another clinical study with an investigational product during the last 4 weeks.
- •4.More than two previous lines of chemotherapy (NOTE: Any immunotherapy administered will not be considered as a prior line of therapy). Use of biological agents, such as bevacizumab, in combination with previous lines of chemotherapy will be allowed.
- •6.Dementia or significantly altered mental status that would prevent the understanding or rendering of informed consent and compliance with the requirements of this protocol.
- •7.Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function. In particular for history of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent.
- •8.Immunocompromised patients,
- •9.Active clinically serious infections (> grade 2 NCI-CTC version 4.03).
- •10.Active viral hepatitis (HBV or HCV infection)
- •11.Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, does not require corticosteroid treatment, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). A scan to confirm the absence of brain metastases is not required.
- •12.Patients with seizure disorders requiring medication (such as steroids or anti-epileptics).
- •13.Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed during the screening phase and on day 1 of the first cycle before the start of treatment. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 5 months after last dose of study drug.
- •14.Patients with evidence or history of bleeding diathesis.
- •15.Patients unable to swallow orally administered medication
- •16.Uncontrolled diabetes (fasting glucose > 2 x ULN).
- •17.Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
- •19.Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry.
- •20.Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed).
- •21.Major surgery within 4 weeks of start of study and patients must have recovered from any effects of any major surgery.
- •22.Investigational drug therapy outside of this trial during or within 4 weeks of study entry.
- •23.Prior exposure to the study drugs or their analogues.
- •24.Patients with known hypersensitivity to trabectedin, olaparib or to their excipients.
- •25.Patients can receive a stable dose of bisphosphonates for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment with the study drugs.
- •26.Substance abuse, medical, ps
研究者
相似试验
进行中（未招募）
1 期
A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE.Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluationMedDRA version: 20.0Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: HLTClassification code 10024628Term: Liposarcomas malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073139Term: Round cell liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005626-29-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI10
进行中（未招募）
1 期
Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomasCTIS2023-509215-81-00Asoc Grupo Espanol De Investigacion En Sarcomas72
进行中（未招募）
1 期
Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs)EUCTR2015-005153-12-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE43
进行中（未招募）
1 期
Study on advanced rearranged Mesenchymal chondrosarcomaPatients with advanced, histological and molecularly (presence of the HEY1-NCOA2 fusion) centrally confirmed diagnosis of MCS, with an evidence of RECIST progression within the 6 months prior to starting the study treatment and pre-treated with anthracycline-based chemotherapyMedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 100000004864EUCTR2019-003733-41-ITITALIAN SARCOMA GROUP20
进行中（未招募）
1 期
Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair MechanismEUCTR2017-001755-31-DERuprecht-Karls-Universität Heidelberg, Medical Faculty108